Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA

Background: The approvals of immune checkpoint inhibitors for several cancer types and the rapidly growing recognition that T cell-based immunotherapy significantly improves outcomes for cancer patients led to a re-emergence of cancer vaccines, including dendritic cell (DC)-based immunotherapy. Bloo...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, Alvaro, Erdmann, Michael, Uslu, Ugur, Vass, Verona, Schuler, Gerold, Schuler-Thurner, Beatrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150785/
https://www.ncbi.nlm.nih.gov/pubmed/32121531
http://dx.doi.org/10.3390/pharmaceutics12030210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150785/
https://www.ncbi.nlm.nih.gov/pubmed/32121531
http://dx.doi.org/10.3390/pharmaceutics12030210

Ejemplares similares